Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-021233
Filing Date
2023-05-11
Accepted
2023-05-11 16:11:18
Documents
60
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q bolt-20230331.htm   iXBRL 10-Q 2002854
2 EX-31.1 bolt-ex31_1.htm EX-31 17091
3 EX-31.2 bolt-ex31_2.htm EX-31 17046
4 EX-32.1 bolt-ex32_1.htm EX-32 9010
5 EX-32.2 bolt-ex32_2.htm EX-32 10283
  Complete submission text file 0000950170-23-021233.txt   8100822

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bolt-20230331_pre.xml EX-101.PRE 296124
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT bolt-20230331_cal.xml EX-101.CAL 47453
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bolt-20230331_def.xml EX-101.DEF 158384
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bolt-20230331_lab.xml EX-101.LAB 407948
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bolt-20230331.xsd EX-101.SCH 54872
54 EXTRACTED XBRL INSTANCE DOCUMENT bolt-20230331_htm.xml XML 1762126
Mailing Address 900 CHESAPEAKE DRIVE REDWOOD CITY CA 94063
Business Address 900 CHESAPEAKE DRIVE REDWOOD CITY CA 94063 650-665-9295
Bolt Biotherapeutics, Inc. (Filer) CIK: 0001641281 (see all company filings)

EIN.: 472804636 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39988 | Film No.: 23911114
SIC: 2834 Pharmaceutical Preparations